Drug Profile
AGN 191743
Latest Information Update: 18 May 2020
Price :
$50
*
At a glance
- Originator Roche Palo Alto LLC
- Developer Allergan; Roche Palo Alto LLC
- Class Antipsoriatics; Corticosteroids
- Mechanism of Action Arachidonic acid inhibitors; Immunosuppressants; Platelet activating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Atopic dermatitis; Psoriasis
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 10 Oct 1995 Discontinued-I for Atopic dermatitis in USA (Topical)
- 10 Oct 1995 Discontinued-I for Psoriasis in USA (Topical)